These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25112450)

  • 1. Ranolazine treatment for myocardial infarction? Effects on the development of necrosis, left ventricular function and arrhythmias in experimental models.
    Hale SL; Kloner RA
    Cardiovasc Drugs Ther; 2014 Oct; 28(5):469-75. PubMed ID: 25112450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel.
    Hale SL; Leeka JA; Kloner RA
    J Pharmacol Exp Ther; 2006 Jul; 318(1):418-23. PubMed ID: 16617168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of ranolazine and propranolol, alone or combined, on the structural and functional alterations of cardiomyocyte mitochondria in a pig model of ischemia/reperfusion.
    Dehina L; Descotes J; Chevalier P; Bui-Xuan B; Romestaing C; Dizerens N; Mamou Z; Timour Q
    Fundam Clin Pharmacol; 2014 Jun; 28(3):257-67. PubMed ID: 23607936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.
    Maier LS
    J Cardiovasc Pharmacol; 2009 Oct; 54(4):279-86. PubMed ID: 19333133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias.
    Stone PH
    Cardiol Clin; 2008 Nov; 26(4):603-14. PubMed ID: 18929234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late sodium current inhibition as a new cardioprotective approach.
    Hale SL; Shryock JC; Belardinelli L; Sweeney M; Kloner RA
    J Mol Cell Cardiol; 2008 Jun; 44(6):954-967. PubMed ID: 18462746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit.
    Hale SL; Kloner RA
    J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):249-55. PubMed ID: 17220471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.
    Belardinelli L; Liu G; Smith-Maxwell C; Wang WQ; El-Bizri N; Hirakawa R; Karpinski S; Li CH; Hu L; Li XJ; Crumb W; Wu L; Koltun D; Zablocki J; Yao L; Dhalla AK; Rajamani S; Shryock JC
    J Pharmacol Exp Ther; 2013 Jan; 344(1):23-32. PubMed ID: 23010360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranolazine: an antianginal drug with antiarrhythmic properties.
    Tamargo J; Caballero R; Delpón E
    Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):815-27. PubMed ID: 21809962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
    Melloni C; Newby LK
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion.
    Wang P; Fraser H; Lloyd SG; McVeigh JJ; Belardinelli L; Chatham JC
    J Pharmacol Exp Ther; 2007 Apr; 321(1):213-20. PubMed ID: 17202401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation.
    Sossalla S; Wagner S; Rasenack EC; Ruff H; Weber SL; Schöndube FA; Tirilomis T; Tenderich G; Hasenfuss G; Belardinelli L; Maier LS
    J Mol Cell Cardiol; 2008 Jul; 45(1):32-43. PubMed ID: 18439620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranolazine: effects on ischemic heart.
    Rognoni A; Barbieri L; Cavallino C; Bacchini S; Veia A; Degiovanni A; Rametta F; Nardi F; Lazzero M; Lupi A; Bongo AS
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):197-203. PubMed ID: 23961914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The beneficial effects of ranolazine on cardiac function after myocardial infarction are greater in diabetic than in nondiabetic rats.
    Mourouzis I; Mantzouratou P; Galanopoulos G; Kostakou E; Dhalla AK; Belardinelli L; Pantos C
    J Cardiovasc Pharmacol Ther; 2014 Sep; 19(5):457-69. PubMed ID: 24651516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion.
    Dhalla AK; Wang WQ; Dow J; Shryock JC; Belardinelli L; Bhandari A; Kloner RA
    Am J Physiol Heart Circ Physiol; 2009 Nov; 297(5):H1923-9. PubMed ID: 19767532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
    Scirica BM; Morrow DA; Hod H; Murphy SA; Belardinelli L; Hedgepeth CM; Molhoek P; Verheugt FW; Gersh BJ; McCabe CH; Braunwald E
    Circulation; 2007 Oct; 116(15):1647-52. PubMed ID: 17804441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
    Thadani U
    Expert Opin Pharmacother; 2012 Dec; 13(17):2555-63. PubMed ID: 23121448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine.
    Belardinelli L; Shryock JC; Fraser H
    Heart; 2006 Jul; 92 Suppl 4(Suppl 4):iv6-iv14. PubMed ID: 16775092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.
    Sossalla S; Maier LS
    Pharmacol Ther; 2012 Mar; 133(3):311-23. PubMed ID: 22133843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?
    Makielski JC; Valdivia CR
    Br J Pharmacol; 2006 May; 148(1):4-6. PubMed ID: 16520741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.